Introduction Biological treatments deeply changed the management of moderate-to-severe
forms of psoriasis. Among the available biological therapies, interleukin (IL)-17 inhibitors …

Generalized pustular psoriasis (GPP) is a severe and rare form of psoriasis, being a
potentially life-threatening condition, characterized by recurring episodes or flares of …

Risankizumab is a humanized IgG monoclonal antibody inhibitor of IL23 and has been
recently approved by the EMA and the FDA for the treatment of moderate to severe plaque …

Psoriasis management may be challenging, particularly for moderate-to-severe forms of the
disease. Indeed, conventional systemic treatments are often avoided for contraindications or …

The treatment of hidradenitis suppurativa (HS) has always been a real challenge for
dermatologists; to date, the only biologic drugs approved for HS are adalimumab, an anti …

Background Nail psoriasis (NP) has a prevalence that ranges from 10 to 82% among
patients with psoriasis (PsO) and is one of the most common difficult to treat site of psoriasis …

Psoriasis is now considered to be the cutaneous phenotype of a systemic inflammatory
condition, recognized under the term Psoriatic Disease (PsD). PsD has several …

COVID-19 pandemic completely changed every aspect of human life. Several measures
were adopted to limit the spreading of the infection. Among these, vaccination was the main …

Background Recent knowledge of psoriasis pathogenesis has led to the development of
selective drugs. Among these, brodalumab is a monoclonal antibody targeting the …

Introduction Generalized pustular psoriasis (GPP) is a rare form of psoriasis (less of 1% of
cases). Currently, GPP is recognized as a clinical entity, distinguished from plaque psoriasis …